CLL watch and wait

Watch and wait is a standard, active monitoring approach used for many people newly diagnosed with chronic lymphocytic leukaemia (CLL) who have early-stage, slow-progressing, and symptom-free disease. Rather than starting immediate treatment, regular blood tests and clinical review track the disease's behaviour over time, with treatment only started if and when there is clear evidence of progression or symptoms developing. This approach reflects strong evidence that early treatment doesn't improve outcomes for this group of patients.

Research has consistently shown that for people with early-stage, asymptomatic CLL, starting treatment immediately does not improve overall survival or outcomes compared with monitoring and starting treatment only when needed, while also avoiding the side effects and burden of unnecessary treatment. Many people with CLL have disease that progresses very slowly, sometimes never requiring treatment during their lifetime. This evidence-based approach avoids exposing people to treatment risks without a corresponding benefit.

Monitoring typically involves regular blood tests (checking lymphocyte counts and other blood parameters) and clinical review, often every three to six months initially, to look for any signs of disease progression such as rising lymphocyte counts, worsening blood counts, enlarging lymph nodes, or new symptoms. The specific monitoring schedule may be adjusted based on individual disease characteristics and how stable things have been. This regular monitoring allows treatment to be started promptly if and when it does become necessary.

Yes, based on substantial evidence, watch and wait is considered a safe and appropriate approach for suitable patients with early-stage, asymptomatic CLL, since it does not compromise long-term outcomes compared with immediate treatment. Regular monitoring ensures that if the disease does start to progress, this is identified promptly and treatment can be started at the appropriate time. Your haematology team will clearly explain what signs they are watching for and when treatment would become necessary.

Indications for starting treatment typically include significantly enlarging lymph nodes or spleen, worsening anaemia or low platelet counts due to bone marrow involvement, rapidly rising lymphocyte counts, or the development of symptoms such as significant fatigue, weight loss, or night sweats. Your haematology team will discuss these specific triggers relevant to your situation during your monitoring appointments. Recognising and reporting new symptoms between scheduled appointments is also an important part of this monitoring process.

Contact your haematology team if you notice new or worsening symptoms such as significant fatigue, unexplained weight loss, night sweats, or rapidly enlarging lymph nodes, rather than waiting for your next scheduled review. This is usually managed within your existing haematology follow-up; a private haematology consultation can also be arranged within about 2 weeks if you want additional or earlier specialist input.